Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 14 · below the Ichimoku cloud · RSI 36 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.4M | 0.00% | 758.86K | — | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ACRV trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.7 | -15.6 | -7.9 | 33.1 | -13.5 | 11.2 | -15.7 | 39.3 | -1.9 | -16.1 | −28.6% | ||
| 2025 | 0.8 | -12.5 | -61.8 | -31.0 | -25.0 | 13.3 | 7.6 | 4.7 | 35.1 | 9.9 | 18.6 | 2.1 | −60.0% |
| 2024 | -25.8 | 33.2 | 47.1 | 27.1 | -15.1 | -24.9 | 44.5 | 13.2 | -26.2 | 14.3 | -5.3 | -20.6 | +22.4% |
| 2023 | 40.6 | 25.4 | -37.5 | -3.0 | -4.3 | 10.0 | -4.0 | -5.8 | -18.4 | -45.2 | -22.7 | 21.5 | −57.3% |
| 2022 | -10.4 | −10.4% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 4, 2026 | Miller MaryOfficer | Sale at price 1.99 per share. | 294 | $585 |
| Aug 30, 2026 | Levin MichaelaOfficer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Aug 24, 2026 | Blume-Jensen PeterChief Executive Officer | Sale at price 2.21 per share. | 14K | $30.97K |
| Aug 17, 2026 | Miller MaryOfficer | Sale at price 2.01 per share. | 185 | $372 |
| Aug 17, 2026 | Devroe EricChief Operating Officer | Sale at price 2.01 per share. | 604 | $1.21K |
| Aug 17, 2026 | Blume-Jensen PeterChief Executive Officer | Sale at price 2.01 per share. | 1.7K | $3.44K |
| Aug 17, 2026 | Gamelin ErickOfficer | Sale at price 2.01 per share. | 400 | $804 |
| Aug 17, 2026 | Peterson KatharineOfficer | Sale at price 2.01 per share. | 101 | $203 |
| Aug 3, 2026 | Levy Adam D.Chief Financial Officer | Sale at price 1.57 per share. | 1.1K | $1.79K |
| Jul 20, 2026 | Miller MaryOfficer | Sale at price 1.76 per share. | 573 | $1.01K |
| May 17, 2026 | Tomsicek Michael JohnDirector | Stock Award(Grant) at price 0.00 per share. | 9.4K | — |
| May 17, 2026 | Mirza Mansoor RazaOfficer | Stock Award(Grant) at price 0.00 per share. | 38.8K | — |
| May 17, 2026 | Shacham SharonDirector | Stock Award(Grant) at price 0.00 per share. | 9.4K | — |
| May 17, 2026 | Magovcevic-Liebisch IvanaDirector | Stock Award(Grant) at price 0.00 per share. | 9.4K | — |
| May 17, 2026 | Ra Capital Management, L.P.Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.00 per share. | 9.4K | — |
| May 17, 2026 | Baum Charles MDirector | Stock Award(Grant) at price 0.00 per share. | 9.4K | — |
| May 17, 2026 | Dirocco DerekDirector | Stock Award(Grant) at price 0.00 per share. | 9.4K | — |
| May 17, 2026 | Miller MaryOfficer | Stock Award(Grant) at price 0.00 per share. | 49.8K | — |
| May 17, 2026 | Devroe EricChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 73K | — |
| May 17, 2026 | Blume-Jensen PeterChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 252.8K | — |
Buy / hold / sell counts
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.